\U-Medico Inc. is a **biophysical characterization and formulation services** provider for biopharmaceuticals and new modalities. Founded in **2006** as a spin-out from **Osaka University**, the company has established itself as a leading analytical and research service provider. Their **unique biophysical characterization services** encompass **analytical ultracentrifugation (AUC), hydrogen-deuterium exchange mass spectrometry (HDX-MS), and particle and aggregate analysis**. U-Medico has been catering to a diverse client base across **Japan** and overseas for **15 years**, offering high-quality analytical and formulation development services for biopharmaceuticals, including antibodies and fusion proteins. The company's expertise in **cutting-edge know-how** and **analytical technologies** enables them to provide total support for safe and reliable biopharmaceutical development.
\
With a focus on the **Biopharma, Biotechnology, and Pharmaceutical industries**, U-Medico Inc. continues to attract recognition and investment. In its most recent funding round on **17 March 2022**, the company secured a **Corporate Round - U investment** from **Coriolis Pharma**. This investment underlines the confidence of industry leaders in U-Medico's potential and signifies a significant milestone for the company. Notably, U-Medico consistently receives requests from more than **40 customers** annually, including domestic pharmaceutical manufacturers, polymeric material manufacturers, chemical manufacturers, medical device manufacturers, and overseas pharmaceutical companies.
Taxonomy: Biopharmaceuticals, Analytical services, Formulation development, Biophysical characterization, Research services, Antibodies, Fusion proteins, Analytical ultracentrifugation, HDX-MS, Particle analysis, Aggregate analysis, Pharmaceutical industry, Quality testing, Gene therapy, Cell therapy
